MX2010009669A - Terapia de combinacion con antagonistas de c-met y egfr. - Google Patents
Terapia de combinacion con antagonistas de c-met y egfr.Info
- Publication number
- MX2010009669A MX2010009669A MX2010009669A MX2010009669A MX2010009669A MX 2010009669 A MX2010009669 A MX 2010009669A MX 2010009669 A MX2010009669 A MX 2010009669A MX 2010009669 A MX2010009669 A MX 2010009669A MX 2010009669 A MX2010009669 A MX 2010009669A
- Authority
- MX
- Mexico
- Prior art keywords
- met
- combination therapy
- egfr antagonists
- egfr
- antagonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/122—Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Abstract
La presente invención se refiere, en general, a los campos de la biología molecular y la regulación del factor de crecimiento Mas específicamente, la invención se refiere a una combinación de estas terapias para el tratamiento de afecciones patológicas, como el cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3444608P | 2008-03-06 | 2008-03-06 | |
US4443808P | 2008-04-11 | 2008-04-11 | |
PCT/US2009/036314 WO2009111691A2 (en) | 2008-03-06 | 2009-03-06 | Combination therapy with c-met and egfr antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010009669A true MX2010009669A (es) | 2010-09-22 |
Family
ID=40688402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010009669A MX2010009669A (es) | 2008-03-06 | 2009-03-06 | Terapia de combinacion con antagonistas de c-met y egfr. |
Country Status (20)
Country | Link |
---|---|
US (3) | US20090226443A1 (es) |
EP (1) | EP2257293A2 (es) |
JP (1) | JP2011513427A (es) |
KR (2) | KR20100135780A (es) |
CN (1) | CN102014913A (es) |
AR (1) | AR070861A1 (es) |
AU (1) | AU2009221808A1 (es) |
BR (1) | BRPI0906099A2 (es) |
CA (1) | CA2716851A1 (es) |
CL (1) | CL2009000542A1 (es) |
CR (1) | CR11717A (es) |
EC (1) | ECSP10010527A (es) |
IL (1) | IL207777A0 (es) |
MA (1) | MA32177B1 (es) |
MX (1) | MX2010009669A (es) |
RU (1) | RU2601892C2 (es) |
SG (1) | SG188802A1 (es) |
TW (1) | TW200940064A (es) |
WO (1) | WO2009111691A2 (es) |
ZA (1) | ZA201006028B (es) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8700335B2 (en) | 2006-05-18 | 2014-04-15 | Caris Mpi, Inc. | System and method for determining individualized medical intervention for a disease state |
US8768629B2 (en) | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
JP2011513432A (ja) * | 2008-03-06 | 2011-04-28 | ジェネンテック, インコーポレイテッド | c−met及びHERアンタゴニストの併用療法 |
RU2547600C2 (ru) * | 2008-10-01 | 2015-04-10 | Эмджен Рисерч (Мьюник) Гмбх | Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью |
US20110229469A1 (en) * | 2008-10-01 | 2011-09-22 | Ludwig Institute For Cancer Research | Methods for the treatment of cancer |
AR073853A1 (es) * | 2008-10-17 | 2010-12-09 | Genentech Inc | Metodo de tratamiento. uso |
KR20110124368A (ko) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | 이중특이적 항―erbb―2/항―c―met 항체 |
CN102378768A (zh) | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-3/抗-c-Met抗体 |
KR101968766B1 (ko) | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | 이종 폴리펩티드의 분비를 위한 방법 및 조성물 |
TWI518325B (zh) | 2010-02-04 | 2016-01-21 | 自治醫科大學 | 對alk抑制劑具有先抗性或後抗性癌症的識別、判斷和治療 |
CA2791863C (en) * | 2010-03-10 | 2022-06-21 | Genmab A/S | Monoclonal antibodies against c-met |
US9175084B2 (en) * | 2010-04-02 | 2015-11-03 | Fujirebio Inc. | Diagnostic marker for effect of anticancer agent |
WO2012003338A1 (en) * | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
DK2612151T3 (en) | 2010-08-31 | 2017-10-02 | Genentech Inc | BIOMARKETS AND METHODS OF TREATMENT |
WO2012064967A2 (en) * | 2010-11-10 | 2012-05-18 | Cedars-Sinai Medical Center | Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases |
CA2829131C (en) | 2011-03-04 | 2018-11-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Amino-quinolines as kinase inhibitors |
CN102796109B (zh) * | 2011-05-23 | 2015-10-07 | 复旦大学 | 4-氨基喹唑啉化合物及其制备方法和用途 |
WO2012170715A1 (en) * | 2011-06-07 | 2012-12-13 | Caris Mpi, Inc. | Molecular profiling for cancer |
KR20140045440A (ko) | 2011-06-30 | 2014-04-16 | 제넨테크, 인크. | 항-c-met 항체 제제 |
TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
CA2847245A1 (en) * | 2011-09-09 | 2013-03-14 | Amgen Inc. | Use of c-met protein for predicting the efficacy of anti-hepatocyte growth factor ("hgf") antibodies in esophageal and gastric cancer patients |
TWI594986B (zh) * | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
EA031184B1 (ru) | 2012-11-21 | 2018-11-30 | Янссен Байотек, Инк. | БИСПЕЦИФИЧЕСКИЕ К EGFR/c-Met АНТИТЕЛА |
US9695228B2 (en) | 2012-11-21 | 2017-07-04 | Janssen Biotech, Inc. | EGFR and c-Met fibronectin type III domain binding molecules |
KR20150118152A (ko) | 2013-02-21 | 2015-10-21 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 키나제 억제제로서의 퀴나졸린 |
CN103113365B (zh) * | 2013-02-22 | 2015-06-17 | 苏州大学 | 罗丹宁喹唑啉胺复合物及其制备方法和用途 |
KR102029137B1 (ko) | 2013-03-27 | 2019-10-08 | 삼성전자주식회사 | EGFR 길항제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물 |
WO2014160729A1 (en) * | 2013-03-28 | 2014-10-02 | Cellworks Research India Pvt. Ltd | Composition and method for treating cancer |
KR102049991B1 (ko) | 2013-03-28 | 2019-12-02 | 삼성전자주식회사 | 항 c-Met/항 Her2 이중 특이 항체 |
KR20140119396A (ko) | 2013-03-29 | 2014-10-10 | 삼성전자주식회사 | 단백질 약물의 액상 제형 |
KR102074421B1 (ko) | 2013-03-29 | 2020-02-10 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 |
KR102060540B1 (ko) | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
CA2923667A1 (en) * | 2013-09-09 | 2015-03-12 | Triact Therapeutics, Inc. | Cancer therapy |
EP3057608A4 (en) | 2013-10-14 | 2017-10-11 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
US9717715B2 (en) * | 2013-11-15 | 2017-08-01 | Samsung Electronics Co., Ltd. | Method of combination therapy using an anti-C-Met antibody |
TW201609805A (zh) | 2013-12-23 | 2016-03-16 | 美國禮來大藥廠 | 結合egfr及met之多功能抗體 |
KR102194142B1 (ko) * | 2014-01-20 | 2020-12-23 | 삼성전자주식회사 | 항 c-Met/항 EGFR 이중 특이 항체 및 c-Src 저해제를 포함하는 병용 투여용 약학 조성물 |
KR102291465B1 (ko) * | 2014-01-24 | 2021-08-18 | 삼성전자주식회사 | c-Met 저해제의 효능 예측을 위한 바이오마커 TFF1 |
PL3116999T3 (pl) | 2014-03-14 | 2021-12-27 | F.Hoffmann-La Roche Ag | Sposoby i kompozycje do wydzielania polipeptydów heterologicznych |
MA39776A (fr) | 2014-03-24 | 2017-02-01 | Hoffmann La Roche | Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf |
KR102223502B1 (ko) | 2014-05-09 | 2021-03-05 | 삼성전자주식회사 | 항 c-Met/항 EGFR/항 Her3 다중 특이 항체 및 이의 이용 |
KR102309881B1 (ko) | 2014-11-21 | 2021-10-06 | 삼성전자주식회사 | c-Met 및 EGFR의 이중 저해제 및 IGF-1R 저해제를 포함하는 병용 투여용 약학 조성물 |
CU24613B1 (es) * | 2016-02-06 | 2022-07-08 | Epimab Biotherapeutics Inc | Proteínas de unión a inmunoglobulinas fabs en tandem (fit-ig) biespecíficas que se unen a cmet y egfr |
WO2017201156A1 (en) * | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
WO2017223180A2 (en) | 2016-06-21 | 2017-12-28 | Janssen Biotech, Inc. | Cysteine engineered fibronectin type iii domain binding molecules |
TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗met抗體,結合met之雙特異性抗原結合分子及其使用方法 |
AU2017378226A1 (en) | 2016-12-14 | 2019-06-20 | Janssen Biotech, Inc. | CD8A-binding fibronectin type III domains |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
JP7113826B2 (ja) | 2016-12-19 | 2022-08-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | プロテインキナーゼ阻害剤および追加的化学療法剤の組み合わせ |
JP6771594B2 (ja) | 2017-02-15 | 2020-10-21 | 大鵬薬品工業株式会社 | 医薬組成物 |
CN108324990A (zh) * | 2018-02-11 | 2018-07-27 | 温州优墨生物科技有限公司 | 一种骨材料脱细胞的方法及制备脱细胞骨粉的方法 |
CN112119098A (zh) * | 2018-03-28 | 2020-12-22 | 田边三菱制药株式会社 | cMET单克隆结合剂的药物缀合物及其用途 |
SG11202112412QA (en) * | 2019-05-14 | 2021-12-30 | Janssen Biotech Inc | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
MX2022002886A (es) | 2019-09-16 | 2022-04-06 | Regeneron Pharma | Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet. |
US11628222B2 (en) | 2019-10-14 | 2023-04-18 | Aro Biotherapeutics Company | CD71 binding fibronectin type III domains |
US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
EP4259147A1 (en) * | 2020-12-11 | 2023-10-18 | Erasca, Inc. | Combination therapies for the treatment of cancer |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US6524832B1 (en) * | 1994-02-04 | 2003-02-25 | Arch Development Corporation | DNA damaging agents in combination with tyrosine kinase inhibitors |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US7087613B2 (en) * | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
UA74803C2 (uk) * | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
LT2857516T (lt) * | 2000-04-11 | 2017-09-11 | Genentech, Inc. | Multivalentiniai antikūnai ir jų panaudojimas |
US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7220410B2 (en) * | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
EP1636593B9 (en) * | 2003-06-06 | 2009-12-16 | Genentech, Inc. | Modulating the interaction between hgf beta chain and c-met |
HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
KR101195291B1 (ko) * | 2003-12-11 | 2012-10-26 | 제넨테크, 인크. | C-met 이량체화 및 활성화를 억제하는 방법 및조성물 |
EP1778270A4 (en) * | 2004-05-05 | 2009-09-02 | Merrimack Pharmaceuticals Inc | BIS-SPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY |
ES2564127T5 (es) * | 2004-06-04 | 2020-03-26 | Genentech Inc | Mutaciones en EGFR |
ZA200701656B (en) * | 2004-08-05 | 2008-09-25 | Genentech Inc | Humanized anti-cment antagonists |
AU2005327973A1 (en) * | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
DE602006016085D1 (de) * | 2005-03-16 | 2010-09-23 | Genentech Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US20060216288A1 (en) * | 2005-03-22 | 2006-09-28 | Amgen Inc | Combinations for the treatment of cancer |
ZA200707953B (en) * | 2005-03-25 | 2009-06-24 | Genenthech Inc | Methods and compositions for modulating hyperstabilized c-met |
TW200806675A (en) * | 2006-01-30 | 2008-02-01 | Array Biopharma Inc | Heterobicyclic thiophene compounds and methods of use |
MX2008011220A (es) * | 2006-03-07 | 2008-09-11 | Array Biopharma Inc | Compuestos de pirazol heterobiciclicos y metodos de uso. |
CN101415730B (zh) * | 2006-03-30 | 2013-04-10 | 诺瓦提斯公司 | c-Met抗体的组合物和使用方法 |
AR059922A1 (es) * | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
US20110053931A1 (en) * | 2006-06-08 | 2011-03-03 | John Gaudino | Quinoline compounds and methods of use |
EP2059533B1 (en) * | 2006-08-30 | 2012-11-14 | Genentech, Inc. | Multispecific antibodies |
US8580263B2 (en) * | 2006-11-21 | 2013-11-12 | The Regents Of The University Of California | Anti-EGFR family antibodies, bispecific anti-EGFR family antibodies and methods of use thereof |
EP2076289B1 (en) * | 2007-04-13 | 2014-11-12 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer resistant to erbb therapeutics |
CN101918403A (zh) * | 2007-09-06 | 2010-12-15 | 阵列生物制药公司 | 作为酪氨酸激酶抑制剂的吡唑并吡啶类化合物 |
AR073231A1 (es) * | 2008-08-29 | 2010-10-20 | Genentech Inc | Metodos diagnosticos y tratamientos para los tumores independientes del vegf (factor de crecimiento endotelial vascular) |
AR073853A1 (es) * | 2008-10-17 | 2010-12-09 | Genentech Inc | Metodo de tratamiento. uso |
TW201544123A (zh) * | 2009-03-20 | 2015-12-01 | Genentech Inc | 抗-her抗體 |
KR20110124368A (ko) * | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | 이중특이적 항―erbb―2/항―c―met 항체 |
KR101968766B1 (ko) * | 2009-11-05 | 2019-04-12 | 제넨테크, 인크. | 이종 폴리펩티드의 분비를 위한 방법 및 조성물 |
BR112012027873A2 (pt) * | 2010-05-14 | 2017-03-21 | Genentech Inc | método para o tratamento de câncer de mama, método de promoção, método de instrução, artigo de fabricação e método de fabricação do artigo de fabricação |
US8580764B2 (en) * | 2010-07-01 | 2013-11-12 | Arqule, Inc. | Combinational compositions and methods for treatment of cancer |
DK2612151T3 (en) * | 2010-08-31 | 2017-10-02 | Genentech Inc | BIOMARKETS AND METHODS OF TREATMENT |
-
2009
- 2009-03-06 TW TW098107445A patent/TW200940064A/zh unknown
- 2009-03-06 JP JP2010549904A patent/JP2011513427A/ja active Pending
- 2009-03-06 KR KR1020107022230A patent/KR20100135780A/ko not_active Application Discontinuation
- 2009-03-06 AU AU2009221808A patent/AU2009221808A1/en not_active Abandoned
- 2009-03-06 CA CA2716851A patent/CA2716851A1/en not_active Abandoned
- 2009-03-06 KR KR1020167020709A patent/KR20160095186A/ko not_active Application Discontinuation
- 2009-03-06 WO PCT/US2009/036314 patent/WO2009111691A2/en active Application Filing
- 2009-03-06 CL CL2009000542A patent/CL2009000542A1/es unknown
- 2009-03-06 SG SG2013013255A patent/SG188802A1/en unknown
- 2009-03-06 AR ARP090100815A patent/AR070861A1/es unknown
- 2009-03-06 RU RU2010140795/15A patent/RU2601892C2/ru not_active IP Right Cessation
- 2009-03-06 BR BRPI0906099-5A patent/BRPI0906099A2/pt not_active IP Right Cessation
- 2009-03-06 EP EP09716498A patent/EP2257293A2/en not_active Withdrawn
- 2009-03-06 MX MX2010009669A patent/MX2010009669A/es not_active Application Discontinuation
- 2009-03-06 CN CN2009801164913A patent/CN102014913A/zh active Pending
- 2009-03-06 US US12/399,866 patent/US20090226443A1/en not_active Abandoned
-
2010
- 2010-08-24 IL IL207777A patent/IL207777A0/en unknown
- 2010-08-24 ZA ZA2010/06028A patent/ZA201006028B/en unknown
- 2010-09-30 MA MA33214A patent/MA32177B1/fr unknown
- 2010-10-05 CR CR11717A patent/CR11717A/es not_active Application Discontinuation
- 2010-10-06 EC EC2010010527A patent/ECSP10010527A/es unknown
-
2014
- 2014-03-05 US US14/198,359 patent/US20150056207A1/en not_active Abandoned
-
2015
- 2015-12-17 US US14/973,459 patent/US20160303127A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ECSP10010527A (es) | 2010-11-30 |
JP2011513427A (ja) | 2011-04-28 |
EP2257293A2 (en) | 2010-12-08 |
ZA201006028B (en) | 2011-11-30 |
WO2009111691A2 (en) | 2009-09-11 |
CA2716851A1 (en) | 2009-09-11 |
RU2010140795A (ru) | 2012-04-20 |
RU2601892C2 (ru) | 2016-11-10 |
US20150056207A1 (en) | 2015-02-26 |
BRPI0906099A2 (pt) | 2015-07-21 |
SG188802A1 (en) | 2013-04-30 |
AR070861A1 (es) | 2010-05-12 |
AU2009221808A1 (en) | 2009-09-11 |
CR11717A (es) | 2010-11-26 |
KR20160095186A (ko) | 2016-08-10 |
TW200940064A (en) | 2009-10-01 |
IL207777A0 (en) | 2010-12-30 |
CN102014913A (zh) | 2011-04-13 |
US20090226443A1 (en) | 2009-09-10 |
US20160303127A1 (en) | 2016-10-20 |
MA32177B1 (fr) | 2011-03-01 |
CL2009000542A1 (es) | 2010-11-05 |
WO2009111691A3 (en) | 2009-11-12 |
KR20100135780A (ko) | 2010-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010009669A (es) | Terapia de combinacion con antagonistas de c-met y egfr. | |
TW200942552A (en) | Combination therapy with c-Met and HER antagonists | |
MX2014002990A (es) | Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf. | |
EP2569014A4 (en) | PROCESSING METHODS | |
MY186456A (en) | Quinazoline carboxamide azetidines | |
WO2010045345A3 (en) | Treatment method | |
MX2013004761A (es) | Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas. | |
PH12015500186A1 (en) | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib | |
MY163852A (en) | Amidophenoxyindazoles useful as inhibitors of c-met. | |
MY184101A (en) | Indoles | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
EA201171367A1 (ru) | Винилиндазолильные соединения | |
MX2013006392A (es) | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. | |
BRPI0908635A8 (pt) | composto, composição farmacêutica e método de tratamento de câncer | |
EA201170831A1 (ru) | Аминопиразольное соединение | |
MX2014011583A (es) | Metodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. | |
MY164086A (en) | Novel antitumoral use of cabazitaxel | |
IL207046A0 (en) | 6,7-dialkoxy quinazoline derivatives useful for treatment of cancer related disorders | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
UA108494C2 (uk) | Застосування (rs)-s-цикропропіл-s-(4-{[4-{[(1r,2r)-2-гідрокси-1-метилпропіл]окси}-5-(трифторметил)піримідин-2-іл]аміно}феніл)сульфоксіміду для лікування пухлин | |
WO2008113013A3 (en) | C-met mutations and uses thereof | |
MX2012013527A (es) | Quinazolinas policíclicas, preparación de las mismas, y uso de las mismas. | |
MX2010004259A (es) | Tratamientos antitumorales mejorados. | |
EA200971067A1 (ru) | Триазолиламинопиримидиновые соединения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |